These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 26917574)

  • 1. A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.
    Cottrell ML; Yang KH; Prince HM; Sykes C; White N; Malone S; Dellon ES; Madanick RD; Shaheen NJ; Hudgens MG; Wulff J; Patterson KB; Nelson JA; Kashuba AD
    J Infect Dis; 2016 Jul; 214(1):55-64. PubMed ID: 26917574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis.
    Srinivas N; Cottrell M; Maffuid K; Prince HA; Nelson JAE; White N; Sykes C; Dellon ES; Madanick RD; Shaheen NJ; Gonzalez D; Kashuba ADM
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31740561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine.
    Dumond JB; Bay CP; Nelson JAE; Davalos A; Edmonds A; De Paris K; Sykes C; Anastos K; Sharma R; Kassaye S; Tamraz B; French AL; Gange S; Ofotokun I; Fischl MA; Vance DE; Adimora AA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention.
    Nicol MR; Corbino JA; Cottrell ML
    J Clin Pharmacol; 2018 Nov; 58(11):1381-1395. PubMed ID: 29901863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
    Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women.
    Anderson PL; Marzinke MA; Glidden DV
    Clin Infect Dis; 2023 May; 76(10):1850-1853. PubMed ID: 36645796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.
    Havens PL; Perumean-Chaney SE; Patki A; Cofield SS; Wilson CM; Liu N; Anderson PL; Landovitz RJ; Kapogiannis BG; Hosek SG; Mulligan K
    Clin Infect Dis; 2020 Feb; 70(4):687-691. PubMed ID: 31179503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women.
    Marrazzo J; Tao L; Becker M; Leech AA; Taylor AW; Ussery F; Kiragu M; Reza-Paul S; Myers J; Bekker LG; Yang J; Carter C; de Boer M; Das M; Baeten JM; Celum C
    JAMA; 2024 Mar; 331(11):930-937. PubMed ID: 38427359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate - emtricitabine for HIV pre-exposure prophylaxis.
    Liegeon G; Antoni G; Pialoux G; Capitant C; Cotte L; Charreau I; Tremblay C; Cua E; Senneville E; Raffi F; Meyer L; Molina JM;
    J Int AIDS Soc; 2020 Feb; 23(2):e25420. PubMed ID: 32086878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
    Chen X; Seifert SM; Castillo-Mancilla JR; Bushman LR; Zheng JH; Kiser JJ; MaWhinney S; Anderson PL
    PLoS One; 2016; 11(11):e0165505. PubMed ID: 27832147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.
    Garrett KL; Chen J; Maas BM; Cottrell ML; Prince HA; Sykes C; Schauer AP; White N; Dumond JB
    J Pharmacol Exp Ther; 2018 Nov; 367(2):245-251. PubMed ID: 30150483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
    Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
    Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
    Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of daily oral HIV PrEP adherence among people who inject drugs in Ukraine: an analysis of biomarkers.
    Morozova O; Kornilova M; Makarenko O; Antoniak S; Liulchuk M; Varetska O; Dumchev K
    J Int AIDS Soc; 2024 Jul; 27 Suppl 3(Suppl 3):e26319. PubMed ID: 39030884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.
    Seifert SM; Glidden DV; Meditz AL; Castillo-Mancilla JR; Gardner EM; Predhomme JA; Rower C; Klein B; Kerr BJ; Guida LA; Zheng JH; Bushman LR; Anderson PL
    Clin Infect Dis; 2015 Mar; 60(5):804-10. PubMed ID: 25409469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.
    Shieh E; Marzinke MA; Fuchs EJ; Hamlin A; Bakshi R; Aung W; Breakey J; Poteat T; Brown T; Bumpus NN; Hendrix CW
    J Int AIDS Soc; 2019 Nov; 22(11):e25405. PubMed ID: 31692269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexposure Prophylaxis.
    Nicol MR; Eneh P; Nakalega R; Kaiser T; Kabwigu S; Isingel E; Beksinska M; Sykes C; Fowler MG; Brown TT; Staley C; Kiweewa Matovu F
    Clin Infect Dis; 2020 Apr; 70(8):1717-1724. PubMed ID: 31131846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Geographic Variation in Qualified Health Plan Coverage and Prior Authorization Requirements for HIV Preexposure Prophylaxis.
    McManus KA; Fuller B; Killelea A; Strumpf A; Powers SD; Rogawski McQuade ET
    JAMA Netw Open; 2023 Nov; 6(11):e2342781. PubMed ID: 37948076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy.
    Cirrincione LR; Podany AT; Havens JP; Bares SH; Dyavar SR; Gwon Y; Johnson TM; Amoura NJ; Fletcher CV; Scarsi KK
    J Antimicrob Chemother; 2020 May; 75(5):1242-1249. PubMed ID: 32065631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT
    JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.